Spojené státy - angličtina - NLM (National Library of Medicine)

home & body company - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - antibacterial helps reduce bacterial on hands

Saúdská Arábie - angličtina - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

moderna biotech, spain - messenger rna (mrna) (embedded in sm-102 lipid nanoparticles) - dispersion for infusion - 30 µg

Spojené státy - angličtina - NLM (National Library of Medicine)

global cosmetics (china) company limited - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic hand sanitizer to help reduce bacteria on skin

Singapur - angličtina - HSA (Health Sciences Authority)

erbe singapore pte. ltd. - general hospital - the smoke evacuation pencil is intended for monopolar cutting and coagulation, and for simultaneous smoke evacuation.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

moderna australia pty ltd - elasomeran, quantity: 0.2 mg/ml - injection, suspension - excipient ingredients: heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; trometamol hydrochloride; trometamol; water for injections; cholesterol; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; sodium acetate trihydrate; sucrose; distearoylphosphatidylcholine; glacial acetic acid - spikevax (elasomeran) covid-19 vaccine has provisional approval for the indication below:,active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment. active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older. the use of this vaccine should be in accordance with official recommendations.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

moderna australia pty ltd - elasomeran, quantity: 0.1 mg/ml - injection, suspension - excipient ingredients: cholesterol; distearoylphosphatidylcholine; trometamol; trometamol hydrochloride; glacial acetic acid; sodium acetate trihydrate; sucrose; water for injections; heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 - spikevax (elasomeran) covid-19 vaccine has provisional approval for the indication below:,active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and postmarket assessment spikevax (elasomeran) covid-19 vaccine is indicated for: active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older. the use of this vaccine should be in accordance with official recommendations.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

moderna australia pty ltd - elasomeran, quantity: 0.1 mg/ml - injection, suspension - excipient ingredients: heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; cholesterol; distearoylphosphatidylcholine; trometamol; trometamol hydrochloride; glacial acetic acid; sodium acetate trihydrate; sucrose; water for injections; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 - spikevax (elasomeran) covid-19 vaccine has provisional approval for the indication below:active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 months of age to <6 years of age. the use of this vaccine should be in accordance with official recommendations. the decision has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment. spikevax (elasomeran) covid-19 vaccine is indicated for: active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older. the use of this vaccine should be in accordance with official recommendations.

Malta - angličtina - Medicines Authority

g. r. lane health products limited sisson road, gloucester, gl2 0gr, united kingdom - cascara, cassia senna, aloin - coated tablet - cascara 130 mg cassia senna 32 mg aloin 10 mg - drugs for constipation

Spojené státy - angličtina - NLM (National Library of Medicine)

moderna us, inc. - elasomeran (unii: epk39pl4r4) (elasomeran - unii:epk39pl4r4) - spikevax is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 18 years of age and older. do not administer spikevax to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of spikevax [see description (11)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to spikevax during pregnancy. women who are vaccinated with spikevax during pregnancy are encouraged to enroll in the registry by calling 1-866-moderna (1-866-663-3762). risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data on spikevax administered to pregnant women are insufficient to inform

Spojené státy - angličtina - NLM (National Library of Medicine)

moderna us, inc. - cx-038839 omicron (xbb.1.5) (unii: 4f9qrs7zv2) (cx-038839 omicron (xbb.1.5) - unii:4f9qrs7zv2) - spikevax is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 12 years of age and older. do not administer spikevax to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of spikevax [see description (11)] or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a moderna covid-19 vaccine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to spikevax during pregnancy. women who are vaccinated with spikevax during pregnancy are encouraged to enroll in the registry by calling 1-866-moderna (1-866-663-3762). risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancie